Person:
BOZKURT, SÜHEYLA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

BOZKURT

First Name

SÜHEYLA

Name

Filters

2012 - 201912020 - 20238
Reset filters

Settings

Start date: 2010 × Subject: Medicine ×

Search Results

Now showing 1 - 9 of 9
  • Thumbnail Image
    PublicationOpen Access
    Mesenchymal stem cells differentiate to retinal ganglion-like cells in rat glaucoma model induced by polystyrene microspheres
    (2023-10-01) ERASLAN, MUHSİN; ÇERMAN, EREN; BOZKURT, SÜHEYLA; AKKOÇ, TUNÇ; ERASLAN M., ÇERMAN E., BOZKURT S., Genç D., Virlan A. T., Demir C. S., Akkoç T., Karaöz E., AKKOÇ T.
    Aim: The study aimed to evaluate the differentiation ability of intravitreally injected rat bone marrow-derived mesenchymal stem cells (rBM-MSCs) to retinal ganglion-like cells in a polystyrene microsphere induced rat glaucoma model. Materials and Methods: The glaucoma rat model was generated via intracameral injection of 7 microliter polystyrene microspheres. Green fluorescence protein-labeled (GFP) rBM-MSCs were transplanted intravitreally at or after induction of ocular hypertension (OHT), depending on the groups. By the end of the fourth week, flat-mount retinal dissection was performed, and labeled against Brn3a, CD90, GFAP, CD11b, Vimentin, and localization of GFP positive rBM-MSCs was used for evaluation through immunofluorescence staining and to count differentiated retinal cells by flow cytometry. From 34 male Wistar albino rats, 56 eyes were investigated. Results: Flow cytometry revealed significantly increased CD90 and Brn3a positive cells in glaucoma induced and with rBM-MSC injected groups compared to control(P = 0.006 and P = 0.003 respectively), sham-operated (P = 0.007 and P < 0.001 respectively), and only rBM-MSCs injected groups (P = 0.002 and P = 0.009 respectively). Immunofluorescence microscopy revealed differentiation of GFP labeled stem cells to various retinal cells, including ganglion-like cells. rBM-MSCs were observable in ganglion cells, inner and outer nuclear retinal layers in rBM-MSCs injected eyes. Conclusion: Intravitreally transplanted rBM-MSCs differentiated into retinal cells, including ganglion-like cells, which successfully created a glaucoma model damaged with polystyrene microspheres. Promisingly, MSCs may have a role in neuro-protection and neuro-regeneration treatment of glaucoma in the future.
  • Thumbnail Image
    PublicationOpen Access
    Langerhans cell histiocytosis located in the spheno-orbital bone and the pons: Illustrative case
    (2023-07-01) ÇEKİÇ, EFECAN; KARAGÖZ, AHMET; SAKAR, MUSTAFA; KAÇAR, KADRİYE EBRU; BOZKURT, SÜHEYLA; DAĞÇINAR, ADNAN; ÇEKİÇ E., Karagoz A., SAKAR M., Senay R. E., AKAR K. E., BOZKURT S., DAĞÇINAR A.
    BACKGROUND This is a case of aggressive Langerhans cell histiocytosis (LCH) with an atypical intracranial location. OBSERVATIONS In this report, the authors present the diagnosis and treatment of a 12-year-old male patient diagnosed with LCH. The patient was admitted to the emergency department with left-sided facial palsy, and a solid lesion with mass effect in the pons was found. A biopsy was performed via suboccipital craniotomy, and the diagnosis was LCH. A chemotherapy regimen was started since the LCH sample was the resistant type. The patient showed improvement in his neurological deficit following treatment. LESSONS This rare localized and aggressive case’s diagnosis process and treatment choices may apply to future cases. https://thejns.org/doi/abs/10.3171/CASE22367.
  • No Thumbnail Available
    PublicationMetadata only
    Challenges in the management of a 7 years old child with thyrotropin-secreting pituitary adenoma and the review of the literature
    (2023-01-01) KIRKGÖZ, TARIK; GÜRPINAR TOSUN, BUŞRA; ELTAN, MEHMET; HALİLOĞLU, BELMA; KAYGUSUZ, SARE BETÜL; SEVEN MENEVŞE, TUBA; BOZKURT, SÜHEYLA; ÖNEŞ, TUNÇ; GÜRAN, TÜLAY; DAĞÇINAR, ADNAN; BEREKET, ABDULLAH; DEMİRCİOĞLU, SERAP; KIRKGÖZ T., Abali S., Seker A., GÜRPINAR TOSUN B., ELTAN M., Helvacioglu D., HALİLOĞLU B., KAYGUSUZ S. B., Yavas Abali Z., SEVEN MENEVŞE T., et al.
    Introduction: Thyrotropin-producing pituitary adenoma (TSHoma) is a very rare disease, representing less than 1% of the pituitary tumours, present with elevated thyroid hormones and normal/high TSH concentrations. Case Presentation: A 7-year-old boy with nervousness was referred by his psychiatrist for elevated free T4, T3 and TSH levels. Initial evaluation revealed an elevated -subunit.Pituitary MRI demonstrated a macroadenoma. The patient underwent a trans-sphenoidal tumour resection (TSS) which showed positive immunohistochemical staining for TSH, growth hormone, and prolactin in tumoral tissue. Euthyroidism was achieved for one year after TSS, then, recurrence of tumour with elevated TSH and thyroid hormone levels necessitated a re-operation with TSS followed by gamma-knife radiosurgery. The euthyroid state was achieved and lasted for 2.5 years this time, but, due to the recurrence, medical treatment had been commenced with cabergoline and octreotide. Euthyroidism was maintained for the last 4 years on monthly octreotide treatment. A repeat MRI demonstrated no pituitary mass but a mass in the sphenoidal sinus had been detected. Removal of this mass by surgery did not achieve euthyroidism. 68Ga-DOTA-TATE PET/CT showed residual tissue extending from the pituitary region to the sphenoid sinus.The patient\"s bone age was advanced 2 years at diagnosis which became 4 years in one year after the diagnosis and remained so throughout follow-up, leading to a final height of -3.3 SDS below his target height at the age of 16 years. Conclusion: The diagnosis, treatment, and follow-up of TSHomas are challenging and short stature due to accelerated bone maturation is a complication of paediatric TSHomas.
  • Thumbnail Image
    PublicationOpen Access
    An Astonishing Extrarenal Wilms Localisation; Spinal Cord
    (2022-06-01) TOKUÇ, AYŞE GÜLNUR; BOZKURT, SÜHEYLA; KAÇAR, KADRİYE EBRU; EKER, NURŞAH; SAKAR, MUSTAFA; TOKUÇ A. G., EKER N., Tas B. T., BOZKURT S., SAKAR M., Aras S., AKAR K. E.
    Wilms\" tumour is a renal tumour mostly seen during the first 5 years of life and it accounts for 95% of renal malignancies during childhood. Its origin is primitive metanephric cells and, very rarely, it may occur in places other than the kidneys. The estimated rate of nephroblastoma outside the kidneys is approximately 0.5 to 1% of Wilms\" tumour cases. In this article, we report on a 3-year-old female patient who first presented with spinal dysraphism and a mass in the lumbar spinal cord with a histopathological diagnosis of nephrogenic rest, and after one year, a Wilms tumour arose in this location. This is a very rare extrarenal Wilms\" tumour location. Here, we report on a case with immature renal cells located in the lumber spinal cord associated with spinal dysraphism and the development of Wilms\" tumour there after one year.
  • Thumbnail Image
    PublicationOpen Access
    Pilocytic Astrocytoma of the Cerebellopontine Angle with cerebrospinal fluid Spread in an Adult: A Case Report
    (2022-12-01) KURŞUN, MELTEM; OĞUZSOY, TUBA; BOZKURT, SÜHEYLA; BAYRAKLI, FATİH; BIYIKLI, ERHAN; Bıyıklı E., Kurşun M., Oğuzsoy T., Bozkurt S., Bayraklı F.
    Introduction Pilocytic astrocytoma of the cerebellopontine angle (CPA) is uncommon, and its spread to the cerebrospinal fluid (CSF) at the time of diagnosis has not been reported in the literature. Case Presentation We report the case of a 33-year-old man with multifocal pilocytic astrocytoma diagnosed by magnetic resonance imaging (MRI) and confirmed by histopathological examination, and present the radiological and histopathological findings. Conclusion In the case herein reported, we observed spread of the pilocytic astrocytoma of the CPA to the CSF at the initial diagnosis, and early detection by MRI is very important regarding the treatment modality and prognosis.
  • No Thumbnail Available
    PublicationMetadata only
    Past, present, and future of therapies for pituitary neuroendocrine tumors: need for omics and drug repositioning guidance
    (2022-03-01) ERDOĞAN, ONUR; ARĞA, KAZIM YALÇIN; BOZKURT, SÜHEYLA; BAYRAKLI, FATİH; YILMAZ, BETÜL; TURANLI, BESTE; Aydin B., Yildirim E., ERDOĞAN O., ARĞA K. Y., Yilmaz B., BOZKURT S., BAYRAKLI F., TURANLI B.
    Innovation roadmaps are important, because they encourage the actors in an innovation ecosystem to creatively imagine multiple possible science future(s), while anticipating the prospects and challenges on the innovation trajectory. In this overarching context, this expert review highlights the present unmet need for therapeutic innovations for pituitary neuroendocrine tumors (PitNETs), also known as pituitary adenomas. Although there are many drugs used in practice to treat PitNETs, many of these drugs can have negative side effects and show highly variable outcomes in terms of overall recovery. Building innovation roadmaps for PitNETs\" treatments can allow incorporation of systems biology approaches to bring about insights at multiple levels of cell biology, from genes to proteins to metabolites. Using the systems biology techniques, it will then be possible to offer potential therapeutic strategies for the convergence of preventive approaches and patient-centered disease treatment. Here, we first provide a comprehensive overview of the molecular subtypes of PitNETs and therapeutics for these tumors from the past to the present. We then discuss examples of clinical trials and drug repositioning studies and how multi-omics studies can help in discovery and rational development of new therapeutics for PitNETs. Finally, this expert review offers new public health and personalized medicine approaches on cases that are refractory to conventional treatment or recur despite currently used surgical and/or drug therapy.
  • No Thumbnail Available
    PublicationMetadata only
    Lenfoplazmosi̇ti̇k lenfomanin santral si̇ni̇r si̇stemi̇ tutulumu olgu sunumu
    (2012-04-19) ÖZGEN, ZERRİN; ATAGÜNDÜZ, IŞIK; BOZKURT, SÜHEYLA; ATASOY, BESTE MELEK; Özgen Z., Adıgüzel C., Karaüç G., Özden S., Atagündüz I., Gül D., Pepedil F., Bozkurt S., Atasoy B. M.
  • Thumbnail Image
    PublicationOpen Access
    Towards development of a standard terminology of the world health organization classification of tumors of the central nervous system in the Turkish language, and a perspective on the practical implications of the WHO classification for low and middle income countries
    (2022-01-01) BOZKURT, SÜHEYLA; Soylemezoglu F., Oz B., Egilmez R., Pekmezci M., BOZKURT S., ERŞEN DANYELİ A., Onguru O., Kulac I., Tihan T.
    © 2022, Federation of Turkish Pathology Societies. All rights reserved.In our manuscript, we propose a common terminology in the Turkish language for the newly adopted WHO classification of the CNS tumors, also known as the WHO CNS 5th edition. We also comment on the applicability of this new scheme in low and middle income countries, and warn about further deepening disparities between the global north and the global south. This division, augmented by the recent COVID-19 pandemic, threatens our ability to coordinate efforts worldwide and may create significant disparities in the diagnosis and treatment of cancers between the \"haves\" and the \"have nots\".
  • No Thumbnail Available
    PublicationMetadata only
    Primer kutanöz anaplastik büyük hücreli lenfoma olgusu
    (2021-11-28) ÖZGEN, ZERRİN; ERGUN, SAFİYE ATLAS TÜLİN; BOZKURT, SÜHEYLA; Karaçam K. A., Özgen Z., Ergun S. A. T., Bozkurt S.
    Marmara Üniversitesi Pendik Eğitim Ve Araştırma Hastanesi Radyasyon Onkolojisi Kliniği 2 Marmara Üniversitesi Tıp Fakültesi Radyasyon Onkolojisi Abd 3 Marmara Üniversitesi Tıp Fakültesi Dermatoloji Abd 4 Marmara Üniversitesi Tıp Fakültesi Patoloji Abd Giriş: Primer cilt lenfomalarında en sık T hücreli lenfomalar görülür. Primer kutanöz anaplastik büyük hücreli lenfoma (pkABHL), MF den sonra 2. en sık görülen T hücreli cilt lenfomasıdır. Lenfomatoid papülozis ile CD30+ lenfoproliferatif hastalıklar grubunu oluşturur. Cilt nüksleri yaygın ancak sistemik tutulumu yaklaşık %10-15 düzeylerindedir. Sistemik anaplastik büyük hücreli lenfoma (ABHL)’ nın tersine pkABHL’ da ALK transformasyonu az görülmektedir. (1) Olgu: 71 yaşında erkek hasta, karın ön duvarda yaklaşık 4-5 aylık süreçte 6x3 cm’lik papüler lezyon gelişmesi üzerine başvurdu.23.08.2021 tarihinde yapılan PET-CT de batın orta hatta 11 x 19 mm boyutlu her iki laterale uzanan en kalın yerinde 4-5 mm kalınlığa ulaşan cilt lezyonunda artmış FDG tutulumu (SUV max=7.9) izlendi. 15.08.2019 tarihinde hastanemizde patoloji birimde yapılan immünohistokimyasal değerlendirmede CD3+, CD30+, CD20-, ALK-, DUSP22 Gen mutasyonu – saptandı. Kemik iliği biyopsisinde tutulum saptanmadı. Sistemik tutulumu da olmaması nedeniyle ön planda \"primer kutanöz ALK – anaplastik büyük hücreli lenfoma\" tanısı aldı. Sistemik tedavi düşünülmeyen hasta radyoterapi için yönlendildi. Hastaya 6/9MeV enerjiyle 0,5 cm bolus kullanılarak definitif konformal 40 Gy/20 fr radyoterapi (RT) uygulandı. Grade 1 dermatit izlendi. 1 ay sonraki kontrolünde tam yanıt alındı. 9 ay sonra batın ön duvarda eski tedavi alanının dışında 2 yeni lezyon gelişti. İntralezyonel metotreksat (MTX) dermatoloji kliniğinde uygulandı. MTX tedavisine kısmen yanıt alınan hasta, MTX dirençli kabul edilerek kliniğimize yönlendirildi. İlk RT den 2 yıl sonra her iki yeni lezyonuna yönelik 9 MeV enerjiyle 0,5 cm bolus kullanılarak 40 Gy/20 fr RT uygulandı. Hemen tedavi bitiminde belirgin klinik regresyon saptandı. Gr 1-2 dermatit izlendi. Tartışma: pkABHL nadir görülen hastalıklardandır. Morfolojik olarak pleomorfik, büyük, anaplastik hücrelerden oluşup çoğunlukla CD30+ yüzey antijeni vardır. Klinikte soliter veye multipl, gruplar halinde; bazen ülsere olabilen nodül veya papüllerden oluşur. Genelde 60 yaş civarında ve erkek/kadın 2/1 oranında görülür. (2) Özellikle ekstremite, gövde ve baş boyun tutulmaktadır. Tedavi bölgesi dışında cilt nüksleri sık görülür. Yavaş seyirli ve iyi prognozlu bir hastalıktır. En sık sistemik tutulum bölgesi bölgesel lenf nodlarıdır. 5 yıllık sağkalım bölgesel lenf nodu tutulsa bile %95 tir. Soliter ve lokalize hastalığın tedavisinde cerrahi veya radyoterapi primer tedavi seçenekleridir. (3,4) pkABHL radyosensitif bir tümördür. Genellikle yapılan çoğu çalışmada kutanöz lenfomalarla birlikte ele alınmış olup 24-36 Gy RT, bazı çalışmalarda ise 40 Gy/20 fr RT uygulanmış ve tam yanıt alınmıştır. Genellikle 6-9MeV enerji ve 0.5-2 cm bolus kullanılmıştır. Radyoterapi iyi tolere edilmektedir ve çoğunlukla grade 1-2 yan etki izlenmiştir. (5,6) Sistemik tedavide CHOP ve CVP rejimi, metotreksat, brentuximab vedotin ve diğer ajanlar kullanılabilir ve yanıt oranları yüksektir. (7) Olgumuzda literatürle uyumlu olarak radyoterapiye çok iyi yanıt alınmıştır ve farklı cilt alanlarında yineleme olmuştur. Sonuç: pkABHL nadir görülen bir hastalık olup radyosensitif olması nedeniyle lokal hastalıkta primer seçeneklerden biridir. 24-40 Gy ortalama RT dozu güvenli şekilde uygulanabilmektedir. Anahtar kelimeler: primer kutanöz anaplastik büyük hücreli lenfoma